Volume 136, Issue 4, Pages (April 2009)

Slides:



Advertisements
Similar presentations
Volume 146, Issue 2, Pages (February 2014)
Advertisements

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.
Mathematical modeling of viral kinetics:
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
Volume 131, Issue 2, Pages (August 2006)
SMAD About Hepatitis C Virus Cell Entry and Liver Disease
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 134, Issue 5, Pages e1 (May 2008)
Volume 144, Issue 5, Pages (May 2013)
Volume 146, Issue 3, Pages e4 (March 2014)
Covering the Cover Gastroenterology
Is HCV Infection a Neurologic Disorder?
Outcomes Among Living Liver Donors
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection  Tobias Boettler, Robert Thimme  Gastroenterology 
Volume 143, Issue 3, Pages e5 (September 2012)
Volume 128, Issue 2, Pages (February 2005)
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 154, Issue 8, Pages e8 (June 2018)
Volume 133, Issue 3, Pages (September 2007)
Covering the Cover Gastroenterology
Volume 134, Issue 5, Pages (May 2008)
Volume 135, Issue 4, Pages (October 2008)
Fasiha Kanwal, MD, MSHS, Hashem B. El-Serag, MD, MPH 
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Volume 150, Issue 4, Pages (April 2016)
Volume 154, Issue 4, Pages (March 2018)
TLL1 rs Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C  Miya John, Mayada Metwally  Gastroenterology 
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Volume 42, Issue 4, Pages (April 2005)
Volume 154, Issue 6, Pages (May 2018)
Volume 134, Issue 7, Pages e2 (June 2008)
Volume 155, Issue 4, Pages e3 (October 2018)
Volume 152, Issue 5, Pages e1 (April 2017)
Volume 142, Issue 6, Pages e3 (May 2012)
Volume 128, Issue 4, Pages (April 2005)
Volume 144, Issue 2, Pages (February 2013)
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Impact of New Hepatitis C Treatments in Different Regions of the World
Christoph Sarrazin, Stefan Zeuzem  Gastroenterology 
Volume 142, Issue 6, Pages (May 2012)
Scott J. Cotler, Manish K. Dhamija, Fabiolla Siqueira, Anna H
Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins  Harel Dahari, Stephen M. Feinstone,
Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review  Gennaro D’Amico, Juan Carlos Garcia-Pagan,
Volume 134, Issue 7, Pages e2 (June 2008)
Effect of Human Immunodeficiency Virus and Antiretrovirals on Outcomes of Hepatitis C: A Systematic Review From an Epidemiologic Perspective  Jennifer.
Volume 128, Issue 1, Pages (January 2005)
Volume 133, Issue 2, Pages (August 2007)
Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle
Volume 133, Issue 6, Pages (December 2007)
Volume 131, Issue 2, Pages (August 2006)
Volume 152, Issue 1, Pages (January 2017)
Volume 138, Issue 2, Pages e6 (February 2010)
Volume 132, Issue 1, Pages 5-6 (January 2007)
Volume 148, Issue 3, Pages (March 2015)
Immune Quiescence and Hepatitis B Virus: Tolerance Has Its Limits
Issue Highlights Clinical Gastroenterology and Hepatology
Volume 143, Issue 3, Pages e5 (September 2012)
Timothy P. Sheahan, Charles M. Rice  Gastroenterology 
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Ethnicity and Body Mass Index Are Associated With Hepatitis C Presentation and Progression  Eric R. Kallwitz, Jennifer Layden–Almer, Manish Dhamija, Jamie.
Volume 144, Issue 1, Pages 9-12 (January 2013)
Volume 150, Issue 7, Pages (June 2016)
Clinical Gastroenterology and Hepatology
Volume 155, Issue 6, Pages (December 2018)
Reply Gastroenterology
Volume 152, Issue 5, Pages e1 (April 2017)
Controversies in Liver Transplantation for Hepatitis C
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Presentation transcript:

Volume 136, Issue 4, Pages 1402-1409 (April 2009) A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease  Harel Dahari, Jennifer E. Layden–Almer, Eric Kallwitz, Ruy M. Ribeiro, Scott J. Cotler, Thomas J. Layden, Alan S. Perelson  Gastroenterology  Volume 136, Issue 4, Pages 1402-1409 (April 2009) DOI: 10.1053/j.gastro.2008.12.060 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 The distribution of baseline HCV-RNA levels. (A) The predicted baseline viral load distribution from 1000 simulated patients with a range of p = 0.1–6 virions/day and β = 1 × 10−9 to 1 × 10−8 mL/day/virions (black bars) is close to the observed baseline HCV-RNA distribution in the United States (red line), digitized from Nainan et al.27 (B) With a larger range of p = 0.1–45 virions/day and the same β = 1 × 10−9 to 1 × 10−8 mL/day/virions the predicted HCV-RNA distribution (blue bars) is skewed right from the actual distribution (red line), and with a range of p = 0.1–6 virions/day and a higher infectivity rate constant, β = 1 × 10−7 to 1 × 10−6 mL/day/virions (green bars) it is skewed to the left because of increased rates of infected cell death, δ, and HCV clearance, c (Table 2). All other model parameters (Table 3) did not significantly change the distribution of HCV-RNA values in (A) and (B) (not shown). (C) Distribution of baseline HCV-RNA in cirrhotic (orange bars) and noncirrhotic (gray bars) patients, from the University of Illinois at Chicago. Gastroenterology 2009 136, 1402-1409DOI: (10.1053/j.gastro.2008.12.060) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 Critical-drug efficacy, baseline HCV-RNA level, and infection-rate constant, β. We randomly chose 1000 parameter sets within the ranges given in Table 3, except p = 0.1–6 virions/day (see Figure 1). We then calculated the critical-drug efficacy (ϵc) and virus steady state level (V) using Equation 2 and Equation S3 (see supplemental material), respectively, for different ranges of the infection rate constant, β. These different ranges affect the percentage of hepatocytes that are HCV infected, as shown in Table 2: high fraction of infected cells (filled squares), moderately high fraction of infected cells (filled circles), and moderate fraction of infected cells (filled triangles). Here, we plot the median ϵc in groups of in silico patients who have baseline viral loads that differ by 0.5 log10 HCV-RNA IU/mL, and we found that this median increases as a sigmoid function of baseline viral load. Thus, higher baseline HCV-RNA levels correlate with higher median ϵc. Gastroenterology 2009 136, 1402-1409DOI: (10.1053/j.gastro.2008.12.060) Copyright © 2009 AGA Institute Terms and Conditions